Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation LtdfiledCriticalUniv Oxford Innovation Ltd
Publication of AR122393A1publicationCriticalpatent/AR122393A1/en
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Abstract
La invención se refiere a una composición que comprende un vector viral, comprendiendo el vector viral ácido nucleico que tiene una secuencia de polinucleótidos que codifica para la proteína de pico del coronavirus SARS-CoV-2, caracterizada porque dicho vector viral es un vector basado en adenovirus, en la que dicho vector basado en adenovirus es ChAdOx 1. La invención también se refiere a los usos de una composición de ese tipo y métodos de tratamiento.The invention relates to a composition comprising a viral vector, the viral vector comprising nucleic acid having a polynucleotide sequence encoding the spike protein of the SARS-CoV-2 coronavirus, characterized in that said viral vector is a vector based on adenovirus, wherein said adenovirus-based vector is ChAdOx 1. The invention also relates to uses of such a composition and methods of treatment.
ARP210100627A2020-03-132021-03-12
COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE
AR122393A1
(en)
recombinant adenovirus, composition, use of adenovirus or composition, method of inducing an immune response in a patient, and non-human simian adenovirus